Hydration Pharmaceuticals Co. Ltd. (HPC) AI Stock Analysis

• Market Cap: AU$2.15M
• Dividend Yield: N/A
• Average Volume (3M): 1.21M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.75
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: N/A
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Food Distribution
• EPS (TTM): >-0.01
• Shares Outstanding: 430,800,930
• 10 Day Avg. Volume: 3,315,133
• 30 Day Avg. Volume: 1,207,806
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.51
• Price to Sales (P/S): 0.44
• P/FCF Ratio: -0.46
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: AU$0.01 ▲(0.00% Upside)

The score is held down primarily by persistently negative operating profitability and ongoing negative operating/free cash flow, which signal continued cash burn and a fragile turnaround. Balance-sheet repair (zero debt and positive equity) helps offset risk, but valuation signals are weak/unclear due to a negative P/E and no dividend data, and technical momentum cannot be evaluated with the missing indicators.

Positive Factors

Product Innovation

The launch of Hydralyte Plus Brain Support positions the company in the growing hydration and nootropics markets, enhancing market presence and growth opportunities.

Balance Sheet Improvement

Zero debt and positive equity reduce financial risk, providing a more stable capital structure and potentially improving financial flexibility.

Net Profit Margin

A strong net profit margin and positive net income in 2024 indicate improved profitability, although sustainability remains a concern.

Negative Factors

Negative Cash Flow

Persistent negative cash flow indicates ongoing cash burn, raising concerns about liquidity and the need for external funding.

Revenue Decline

A sharp revenue decline in 2024 suggests instability in top-line growth, potentially impacting long-term business sustainability.

Shareholder Structure Changes

Changes in substantial shareholders may impact market perception and influence, potentially affecting strategic decisions and stability.

Hydration Pharmaceuticals Co. Ltd. Business Overview & Revenue Model

Company Description

Hydration Pharmaceuticals Co. Ltd. (HPC) is a company specializing in the development, manufacturing, and distribution of innovative hydration solutions. Operating within the health and wellness sector, HPC focuses on providing high-quality, scientifically-backed products designed to improve hydration and overall well-being. Their core product offerings include electrolyte-infused beverages, hydration powders, and supplements tailored to meet the needs of diverse consumer groups, including athletes, health enthusiasts, and individuals seeking enhanced hydration solutions.

How the Company Makes Money

HPC generates revenue primarily through the sale of its hydration products, which are distributed across various channels including retail stores, e-commerce platforms, and direct-to-consumer sales. Key revenue streams include wholesale partnerships with retailers, online sales through the company's website and other online marketplaces, and subscriptions for regular product deliveries. Additionally, HPC may engage in strategic partnerships or collaborations with health and wellness brands to expand its market reach and enhance product offerings, contributing to its earnings.

Hydration Pharmaceuticals Co. Ltd. Financial Statement Overview

Summary

Hydration Pharmaceuticals Co. Ltd. displays significant financial challenges, with declining revenues and profitability, high cash burn, and financial instability. Despite some relief from the absence of debt, the sustainability of operations remains a concern.

Income Statement

Hydration Pharmaceuticals Co. Ltd. has faced declining revenues and profitability over the years. The revenue growth rate has been negative, with a significant drop from 2023 to 2024. Gross profit margin shows some resilience, but the net profit margin remains negative due to substantial losses. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company's balance sheet reveals a decline in total assets over time, but no debt in the latest year, reducing leverage risk. However, negative equity in some years indicates financial instability. The equity ratio improved in 2024, but the return on equity could not be assessed due to negative or missing equity data.

Cash Flow

Cash flow analysis shows persistent negative operating cash flows, highlighting operational inefficiencies. Free cash flow has remained negative, indicating cash burn. The company has a high dependency on financing activities, which may not be sustainable in the long term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-235.84K	3.20M	10.04M	9.10M	6.13M	3.76M
Gross Profit	-248.26K	1.62M	5.39M	4.70M	2.79M	1.34M
EBITDA	-3.91M	-3.91M	-7.46M	-10.52M	-6.08M	-3.28M
Net Income	4.34M	2.67M	-8.10M	-10.61M	-8.97M	-743.66K
Balance Sheet
Total Assets	3.93M	5.00M	6.69M	10.39M	15.31M	4.45M
Cash, Cash Equivalents and Short-Term Investments	2.11M	3.22M	1.84M	4.69M	10.67M	1.64M
Total Debt	0.00	0.00	3.89M	3.71M	0.00	0.00
Total Liabilities	1.22M	2.25M	7.05M	6.41M	2.08M	2.44M
Stockholders Equity	2.71M	2.74M	-358.25K	3.98M	13.23M	2.00M
Cash Flow
Free Cash Flow	-1.64M	-3.02M	-5.73M	-9.75M	-8.08M	-3.88M
Operating Cash Flow	-1.64M	-3.02M	-5.73M	-9.75M	-8.08M	-3.86M
Investing Cash Flow	0.00	9.44M	0.00	0.00	-2.15K	2.73M
Financing Cash Flow	514.25K	-3.63M	2.72M	4.08M	17.03M	0.00

Hydration Pharmaceuticals Co. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
LDX	46 Neutral	AU$216.48M	-18.01	-111.23%	―	12.96%	40.81%
HPC	45 Neutral	AU$2.15M	―	―	―	―	―
HXL	40 Underperform	AU$2.17M	-4.33	-28.49%	―	―	46.43%

Hydration Pharmaceuticals Co. Ltd. Corporate Events

Hydration Pharmaceuticals Announces Change in Substantial Shareholders

Hydration Pharmaceuticals Co. Ltd. has announced a significant change in its shareholder structure, with David Hemming and Syrax Investments Pty Ltd ceasing to be substantial holders. This change reflects a series of sales transactions reducing their combined stake in the company, potentially impacting the company’s shareholder dynamics and market perception.

JAF Capital Pty Ltd Ceases Substantial Holding in Hydration Pharmaceuticals

Hydration Pharmaceuticals Co. Ltd. has announced that JAF Capital Pty Ltd has ceased to be a substantial holder in the company as of October 6, 2025. This change involved an on-market sale of 2,049,263 voting securities, valued at $25,291.01, which may impact the company’s shareholder structure and influence in the market.

Hydralyte USA Boosts Sales with New Brain Support Product Launch

Hydralyte USA has reported a significant increase in sales for Q3 CY25, with a notable 11% rise compared to the previous year, driven by the launch of its new high-margin product, Hydralyte Plus Brain Support. This product, which combines electrolytes with nootropics like Lion’s Mane, Reishi, and Cordyceps, positions the company at the intersection of the growing hydration and functional nootropics markets, potentially enhancing its market presence and offering new growth opportunities.